New stem cells are able to make new beta cells, the new beta cells are able to sense blood sugar levels and react accordingly
Diabetes is currently one of the most widespread diseases, and its prevalence is rapidly growing around the world. It is a common life-long condition and the number of children diagnosed with type 1 diabetes is increasing. For many, this means living with daily insulin injections and the possibility of long-term health damage.
Type 1 diabetes is an autoimmune disease that results from T cell autoimmunity mediated destruction of the vast majority of insulin-producing pancreatic β-cells.
Therefore, the development of new therapies to control T cell autoimmunity and to preserve the remaining β-cell function is of great significance in managing patients with type 1 diabetes.
Those diagnosed with T1DM are relying on exogenous insulin.
Adipose tissue derived mesenchymal stem cells have been shown in many studies as potential cure for T1DM, which could not only address the need for β-cell replacement but also the regulation of the autoimmune response to cells which produce insulin. Mesenchymal stem cells are able to control T cell autoimmunity.
In both forms of diabetes, unless treated, blood sugar will rise uncontrollably, and over time can lead to complications such as cardiovascular, liver and kidney disease (diabetic nephropathy), as well as circulatory problems that may require limb amputation, vision loss, blindness (diabetic retinopathy), and nerve damage (diabetic neuropathy).
People with type 1 diabetes must test their blood sugar levels several times a day and inject insulin when it is needed. Unfortunately, it can still be hard to keep the blood sugar level normal, even with regular injections.
Over time, a high level can cause serious damage to the heart, eyes, blood vessels, kidneys and nerves, whilst injecting too much insulin can lead to a level that’s too low (hypoglycaemia) and it can be fatal.
It is possible to treat type 1 diabetes by transplanting islet cells or even a whole pancreas to the patient from a donor. Transplants can enable the body to regain control of blood sugar levels so that insulin injections are no longer needed. Islet transplantation is not very common, because the whole pancreas transplants involve major surgery and carry significant risk. Also, the number of donors is heavily outweighed by the demand and transplants require the immune system to be suppressed so that the new ‘alien’ organ is not rejected. Immunity suppressing drugs leave the recipient vulnerable to infections and often have side effects.
One of the biggest problems faced by islet transplantation is the lack of donors. Instead of using donor cells, own stem cells can be used in diabetes therapy, bypassing all the complications, rejections and side effects.
The research showed that stem cells present in the patient’s pancreas are able to make new beta cells. Beta cell progenitors have been found in the pancreas of both rodents and humans; progenitor cells have some stem cell properties and can self-renew (copy themselves) indefinitely. The stem cells from the patient’s own adipose tissue or bone marrow can ‘re-educate’ the immune system so that it no longer attacks the beta cells. The new beta cells are able to sense blood sugar levels and react accordingly.
Clinical trials inserting mesenchymal stem cells into type 1 diabetes patients take advantage of two assets these cells possess. Firstly, they have the regenerative potential to repair beta cells, and secondly they can modulate the immune system by inhibiting the responses that lead to the autoimmune attack on pancreatic beta cells.
Stem cells are a part of a human body naturally, and they have the unique ability to find and repair the place of damage inside the system. For results to fully develop, it usually takes up to four months after the stem cells are injected into human organism during treatment. In the course of that time, a patient notices continuous new improvements. Since these stem cells come from patient’s own body, there is also no risk of rejection or side effects. The whole procedure is very quick, painless, simple and safe, and it is completed within only few hours. This approach promotes beta cell function, thereby reducing or eliminating the requirement for exogenous insulin.
Swiss Medica Clinic has developed the Adult Autologous Stem Cell Therapy program to treat a variety of conditions, one of them being diabetes type 1. During stem cell treatment, a patient receives 200 – 300 million stem cells. This quantity of the restored plain cells not only covers daily losses, but also exceeds them by thousands of times, renewing almost 15 – 20 years worth. This causes symptoms of a disease to improve and the whole body and all of the organs become healthier and rejuvenated, because the new and active cells replace the old and damaged ones.
In Swiss Medica Clinic we deliver treatment with proven results associated with the assistance of highly qualified professionals who realize the importance of personalized care, quality and confidence and this leads to top standards of treatment.
Swiss Medica Clinic is an excellent centre that offers patients the most innovative therapies.
Generally, in our medical centres we use the unique technology of application of autologous photo activated stem cells previously extracted from fat cells using mini liposuction.
The highest standards of treatment and investigative research are upheld at all times.
The package includes:
Optional additional therapy:
What they say about us
It's all been very nice, everybody has been very kind.
I don't think that anyone could fail to be impressed by the level of service and treatments and expertise everyone seems to have here, and, obviously, having medical treatment is not something that people want to have, but at the same time it's been as enjoyable as it could be to do that.continue
I chose the Moscow clinic because there is extra treatments available here, mainly with the umbilical cord stem cells, which wasn’t available anywhere else and I’d heard that’s the most effective.continue
I’m Oliver Lee and I’m from Bristol in the UK.
First treatment I’ve had was in Switzerland for 2 weeks and my combined insulin dosage went down by 25%, from 60 to 45, on average.continue
All form fields are required.